OVERVIEW

Impacting COPD Care: Addressing Alpha-1 Antitrypsin Deficiency is organized by National Association for Continuing Education (NACE).

Start Date: 12/15/2019
Expiration Date: 12/14/2020

Accreditation:
The National Association for Continuing Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The National Association for Continuing Education is approved as a provider of nurse practitioner continuing education by the American Association of Nurse Practitioners. AANP Provider Number 121222. This program has been approved for 1.0 contact hour of continuing education which includes 0.75 pharmacology hours.

Course Description:
Alpha-1 antitrypsin deficiency (AATD) is characterized by low serum levels of alpha-1 antitrypsin (AAT), a serine protease inhibitor responsible for inhibiting the proteolytic enzyme elastase. The clinical effects of AATD are most frequently found in the lungs, where AATD is associated with an increased risk of developing chronic obstructive pulmonary disease (COPD). Severe AATD poses a significant threat to health, with airflow obstruction being a major determinant of mortality. Over 250,000 individuals in the United States may have AATD, but the disease often remains unrecognized or undertreated.

This activity will address the pathophysiology of AATD, its impact on COPD risk, early detection, and the latest treatment options.

Learning Objectives:
After completing this program participants should be able to:
• Discuss the pathophysiology of alpha-1 antitrypsin deficiency (AATD) and its impact on chronic obstructive pulmonary disease (COPD) risk
• Interpret the clinical significance of laboratory test results for AATD
• Discuss treatment options for AATD and latest GOLD guideline recommendations
• Discuss strategies to enhance detection and treatment of AATD in clinical practice